In 2022, the brain implants market was valued at over USD 5.7 billion, and its rapid expansion is fueled by several key factors. One of the most significant drivers is the rising incidence of nervous ...

Discover the top 3 undervalued Health Care Equipment & Supplies stocks for Wednesday, March 19 based on AAII’s Stock Grades.

NVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 results amid a weak SCS market.

The Smart Orthopedic Implants market is expected to grow from an estimated USD 26.21 Billion in 2024 to USD 40.66 Billion in ...

Nevro had a negative return on equity of 23.52% and a negative net margin of 16.54%. The company had revenue of $105.55 million for the quarter, compared to analysts’ expectations of $102.61 ...

NVRO's fourth-quarter earnings surpass the Zacks Consensus Estimate, while worldwide revenues decline year over year. The company continues to incur losses at the operating level.

Total U.S. permanent implant procedures declined 7% year over year, while U.S. trial procedures decreased 14.2% year over year. During the fourth quarter of 2024, Nevro made significant ...

Nevro (NVRO) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.15 per share a year ago. These figures are adjusted ...

The Redwood City, California-based company said it had a loss of $1.41 per share. Losses, adjusted for one-time gains and costs, came to 64 cents per share. The results surpassed Wall Street ...

Management uses certain non-GAAP financial measures, most specifically adjusted EBITDA, as a supplement to GAAP financial measures to further evaluate the Company's operating performance period ...